ROCKVILLE, Md., April 13, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment of cancer, announced today that it will present three poster presentations at the 2016 American Association for Cancer Research (AACR) Annual Meeting, which is being held April 16 - 20, 2016 in New Orleans, Louisiana.
The details for Rexahn’s poster presentations at the AACR Annual Meeting are as follows:
Title: Phase Ib/II Study of RX-0201 (Archexin ® ), a Novel Akt-1 Antisense Combined with Everolimus to Treat Metastatic Clear Cell Renal Carcinoma – Phase Ib Results Date and Time: Tuesday, April 19, 2016, 1:00 pm – 5:00 pm CT Location: Section 13 Session Title: Late Breaking and Clinical Trials Abstract ID: CT 114
Title: Folate Receptor-Targeted Lipid Coated Albumin Nanoparticles (F-LCAN) for Therapeutic Delivery of RX-0201 (Archexin ® ) an Antisense Oligonucleotide Against Akt-1 Date and Time: Monday, April 18, 2016, 8:00 am – 12:00 pm CT Location: Convention Center, Halls G-J, Poster Section 19 Session Title: Cancer Chemistry – Drug Delivery 1 Abstract ID: 1322
Title: Inhibition of DNA Methyltransferase by RX-3117 Leads to Upregulation of Hypomethylated Targets Date and Time: Wednesday, April 20, 2016 8:00 am – 12:00 pm CT Location: Convention Center, Halls G-J, Poster Section 17 Session Title: Experimental and Molecular Therapeutics – HDAC, Methyltransferase Inhibitors and Novel Anticancer Agents Abstract ID: 4725
Copies of the abstracts are available and can be viewed online through the AACR website at www.aacr.org . Copies of the poster presentations will be available on Rexahn’s corporate website at www.rexahn.com under ‘Events and Presentations’ upon completion of the sessions.
Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals Inc. (NYSE MKT:RNN) is a clinical stage biopharmaceutical company dedicated to developing novel, best-in-class therapeutics for the treatment of cancer. The Company’s mission is to improve the lives of cancer patients by developing next generation cancer therapies that are designed to maximize efficacy while minimizing the toxicity and side effects traditionally associated with cancer treatment. Rexahn’s product candidates work by targeting and neutralizing specific proteins believed to be involved in the complex biological cascade that leads to cancer cell growth. Pre-clinical studies indicate that certain of Rexahn’s product candidates may be effective against multiple types of cancer, drug resistant cancers, and difficult-to-treat cancers, and others may augment the effectiveness of current FDA-approved cancer treatments. The Company has a broad oncology pipeline that includes three anti-cancer compounds currently in clinical development: Supinoxin; RX-3117; and Archexin ® , and a novel nanopolymer-based drug delivery platform technology that may increase the bio-availability of FDA-approved chemotherapies. For more information about the Company and its oncology programs, please visit www.rexahn.com .
Safe Harbor
To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about Rexahn’s plans, objectives, expectations and intentions with respect to cash flow requirements, future operations and products, enrollments in clinical trials, the path of clinical trials and development activities, anticipated market sizes, and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause Rexahn’s actual results to be materially different than those expressed in or implied by Rexahn’s forward-looking statements. For Rexahn, particular uncertainties and risks include, among others, understandings and beliefs regarding the role of certain biological mechanisms and processes in cancer; drug candidates being in early stages of development, including in pre-clinical development; the ability to initially develop drug candidates for orphan indications to reduce the time-to-market and take advantage of certain incentives provided by the U.S. Food and Drug Administration; and the ability to transition from our initial focus on developing drug candidates for orphan indications to candidates for more highly prevalent indications. More detailed information on these and additional factors that could affect Rexahn’s actual results are described in Rexahn’s filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. Rexahn undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact: Stacey Jurchison Rexahn Investor Relations 240-268-5300 x 324 Jurchisons@rexahn.com
